Replimune adds a $55M round and some ex­pert help as it pur­sues next-gen on­colyt­ics R&D

Some of the pi­o­neers in on­colyt­ics drug de­vel­op­ment have gone back to the ven­ture well to fi­nance their lat­est play in the field. Replimune, which got start­ed in Ox­ford and is based in Woburn, MA, tanked up with $55 mil­lion in ven­ture cash. That mon­ey is be­ing used to po­si­tion the com­pa­ny for its first round of clin­i­cal work.

Replimune is bring­ing in a rec­og­nized ex­pert in the im­muno-on­col­o­gy field as CMO along­side the round. The biotech re­cruit­ed Howard Kauf­man, who had been chief of the Di­vi­sion of Sur­gi­cal On­col­o­gy at the Rut­gers Robert Wood John­son Med­ical School and from 2014-2016 was pres­i­dent of the So­ci­ety for the Im­munother­a­py of Can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER